Triethylamine → tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(benzyloxy)pyridin-3-yl]-3-tert-butoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

HRID 526375Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 526375
[NH2:1][C@H:2]([C:11]1[CH:12]=[N:13][CH:14]=[C:15]([O:17][CH2:18][C:19]2[CH:24]=[CH:23][CH:22]=[CH:21][CH:20]=2)[CH:16]=1)[CH2:3][C:4]([O:6][C:7]([CH3:10])([CH3:9])[CH3:8])=[O:5].O=C1CCC(=O)N1[O:32][C:33]([C@@H:35]1[CH2:40][CH2:39][CH2:38][N:37]([C:41](=[O:57])[CH2:42][CH2:43][CH:44]2[CH2:49][CH2:48][N:47]([C:50]([O:52][C:53]([CH3:56])([CH3:55])[CH3:54])=[O:51])[CH2:46][CH2:45]2)[CH2:36]1)=O.C(N(CC)CC)C>CN(C=O)C.ClCCl>[CH2:18]([O:17][C:15]1[CH:16]=[C:11]([C@@H:2]([NH:1][C:33]([C@@H:35]2[CH2:40][CH2:39][CH2:38][N:37]([C:41](=[O:57])[CH2:42][CH2:43][CH:44]3[CH2:49][CH2:48][N:47]([C:50]([O:52][C:53]([CH3:55])([CH3:54])[CH3:56])=[O:51])[CH2:46][CH2:45]3)[CH2:36]2)=[O:32])[CH2:3][C:4]([O:6][C:7]([CH3:10])([CH3:9])[CH3:8])=[O:5])[CH:12]=[N:13][CH:14]=1)[C:19]1[CH:24]=[CH:23][CH:22]=[CH:21][CH:20]=1

Komponenten

6

Edukt 3

HCID 8471TriethylamineHCID 71268086tert-butyl (3S)-3-amino-3-(5-phenylmethoxypyridin-3-yl)propanoateHCID 89407588tert-butyl 4-{3-[(3R)-3-{[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

Produkt 1

HCID 71258943tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(benzyloxy)pyridin-3-yl]-3-tert-butoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 6228DimethylformamideLösungsmittelHCID 6344DichloromethaneLösungsmittel

Versuchsvorschrift

To tert-butyl (3S)-3-amino-3-[5-(benzyloxy)pyridin-3-yl]propanoate (1.15 g, 3.5 mmol) in DMF (13.4 mL) was added tert-butyl 4-{3-[(3R)-3-{[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate and triethylamine (1.46 mL, 10.5 mmol) in dichloromethane (13.5 mL) at 0° C. After 3 hours the mixture was quenched by addition of saturated aqueous ammonium chloride solution, phases were separated and the aqueous phase was extracted with diethyl ether. Combined organic extracts were dried over sodium sulphate, concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 20 to 100% followed by methanol in ethyl acetate 0 to 20%) to yield 1.76 g tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(benzyloxy)pyridin-3-yl]-3-tert-butoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

Aufarbeitung

  1. customAfter 3 hours the mixture was quenched by addition of saturated aqueous ammonium chloride solution, phases
  2. customwere separated
  3. extractionthe aqueous phase was extracted with diethyl ether
  4. dry with materialCombined organic extracts were dried over sodium sulphate
  5. concentrationconcentrated under reduced pressure
  6. customthe residue was purified by chromatography on silica gel (ethyl acetate in hexane, 20 to 100% followed by methanol in ethyl acetate 0 to 20%)

Quellen und Nachweise

ORD-Eintrag
ord-32c3f8ca8d3b415185a50a2738797105
Quelldatensatz
uspto-grants-2016_05
Patentnummer
US09345793B2

Notizen zur Reaktion

Wird geladen…